YOSHITERU SHIMOIDE M.D. (霜出義輝内科クリニック）

SUMMARY
1, Eradicative medicine of Alzheimer-type dementia, mild cognitive impairment, bronchial asthma and the chronic kidney disease absent to date were completed.
A cognitive function of Alzheimer-type dementia and the mild cognitive impairment is recovered easily.
2,The etiology of Alzheimer-type dementia and the mild cognitive impairment was brain cells disorder with inflammatory cytokine.
3，Amyloid β deposition in the brain was a result, not a cause of Alzheimer disease.
4, It is concluded that anti-β amyloid antibody, which is still in clinical trials, dose not cure Alzheimer-type dementia and mild cognitive impairment, like various anti-β amyloid antibodies to date.
5，Glaucoma and Parkinson's disease were also caused by inflammatory cytokine disorder.　

Therefore, these diseases also recover easily.

Obtained important results are written down in this homepage by my treatment of approximately 20 years for Alzheimer-type dementia, mild cognitive impairment, OAB ( over active bladder) and the chronic kidney disease, and the like.
95% or more of patients with Alzheimer-type dementia and mild cognitive impairment recover.
As a fact by the data analysis, the cause of Alzheimer-type dementia was cytokine disease which assumed hyperactivity (include inflammation) in immune system a base.

The science is accumulation of facts.

Obtained patents
☆
UNITED STATES PATENT PATENT NUMBER.: US 10,660,929 B2
KAMPO MEDICINE FOR IMPROVING COGNITIVE FUNCTION IN ALZHEIMER-TYPE DEMENTIA OR MILD COGNITIVE IMPAIRMENT AND TREATING AT LEAST ONE DISEASE FROM THE GROUPE CONSISTING OF OVERACTIVE BLADDER, CONSTIPATION, AND CHRONIC KIDNEY DISEASE COMPLICATED BY THEM WITH ONE DRUG

☆
EUROPEAN PATENT PATENT NUMBER.: 3545964
KAMPO MEDICINE FOR IMPROVING COGNITIVE FUNCTION IN ALZHEIMER-TYPE DEMENTIA OR MILD COGNITIVE IMPAIRMENT AND TREATING AT LEAST ONE DISEASE FROM THE GROUPE CONSISTING OF OVERACTIVE BLADDER, CONSTIPATION, AND CHRONIC KIDNEY DISEASE COMPLICATED BY THEM WITH ONE DRUG

☆
JAPANESE PATENT PATENT NUMBER.: 6401414
アルツハイマー型認知症または軽度認知障害の認知機能を改善するとともに、それらに合併する過活動膀胱、および便秘症からなる群の少なくとも１つの疾患を一剤で治療する漢方薬
KAMPO MEDICINE FOR IMPROVING COGNITIVE FUNCTION IN ALZHEIMER-TYPE DEMENTIA OR MILD COGNITIVE IMPAIRMENT AND TREATING AT LEAST ONE DISEASE FROM THE GROUPE CONSISTING OF OVERACTIVE BLADDER, CONSTIPATION, AND CHRONIC KIDNEY DISEASE COMPLICATED BY THEM WITH ONE DRUG
人類史上初めてアルツハイマー型認知症および軽度認知障害を軽快させる薬剤を発明しました。
95％以上の確率でアルツハイマー型認知症、及び、軽度認知障害を回復させることができます。

☆
JAPANESE PATENT PATENT NUMBER.: 6691182
慢性腎臓病と過活動膀胱と便秘症からなる群の少なくとも１つの疾患を一剤で治療する漢方薬
KAMPO MEDICINE TREATING AT LEAST ONE DISEASE FROM THE GROUPE CONSISTING OF OVERACTIVE BLADDER, CONSTIPATION, AND CHRONIC KIDNEY DISEASE COMPLICATED BY THEM WITH ONE DRUG
日本においても1300万人いるCKD（慢性腎臓病）患者を治癒、軽快、もしくは進行阻止します

☆
JAPANESE PATENT PATENT NUMBER, : 6154566
慢性甲状腺炎による甲状腺機能低下症のホルモン異常を正常化させる漢方薬
(The Chinese medicine which lets hormone abnormality of the hypothyroidism by the chronic thyroiditis normalize)

Eradicative medicine (RO-8) of Alzheimer-type dementia is immunomodulator of the mechanism that is totally different from the antiphlogistic and immunosuppressive drug to date immunologically.
(What I call Herbal remedies RO-8 was a compound of Ryokeijutsukanto and Orengedokuto, and R stands for Ryokeijutsukanto and O for Orengedokuto. The compound is composed of 8 kinds of herbs.)
Aspirin is made from the bark of the tree of willow, and galanthamine (galantamine) which is Alzheimer-type dementia therapeutic drug is made by candlemas bells (pine snow grass), and Vincristine of the antitumor agents is made from a nandin,　and tranilast which is an allergy therapeutic drug made from an apocynaceous Madagascar periwinkle (Catharanthus roseus). Thus, plant origin medical supplies are present in the drug used currently in the world a lot. In the same way as them, this herbal remedies is antiphlogistic derived from the plant using the crude drug.

The cause that all large number of therapeutic medicine development for Alzheimer-type dementia to date failed in was because we got a wrong etiology of Alzheimer-type dementia.

RO-8 makes 87.2% of dermatitis heal in atopic dermatitis as presented in AAAAI 2009 and makes 12.8% make significant improvement. Also, RO-8 can make 96% of patients with moderate and severe bronchial asthma heal as presented in AAAAI 2012. Furthermore, RO-8 can make 91.2% and a high rate normalize thyroid hormone in hypothyroidism (JAPANESE PATENT NUMBER.: 6154566).
Most causes are chronic thyroiditis, and, in hypothyroidism, the chronic thyroiditis is commonly shown to be caused by inflammatory cytokine such as TNF - α, and the like due to the immune response for the self. When consider this, in the chronic thyroiditis caused by inflammatory cytokine, RO-8 is thought to decrease inflammatory cytokine as showed to JAPANESE PATENT (PATENT NUMBER.: 6154566). Furthermore, RO-8 make anti-thyroid antibodies disappear.
In other words, RO-8 makes inflammation of atopic dermatitis heal and makes inflammation of the bronchus of the bronchial asthma heal and RO-8 normalize cytokine of the chronic thyroiditis and do a thyroid function normally. From this fact, RO-8 is thought to be the medicine which can normalize an immune response.

 

Furthermore, this medicine with these effects can make CKD normalize as showed in United States Patent (PATENT NUMBER.: US 10,660,929 B2), European Patent (PATENT NUMBER.: 3545964). At the same time this medicine heal Alzheimer-type dementia and mild cognitive impairment or improve it.
By this fact, I can conclude that the basic etiology of Alzheimer-type dementia and the mild cognitive impairment is hyperactivity of the immune system producing inflammatory cytokine.

Studies in the world to date.

Kamer et al. reported that periodontal disease became the exacerbation factor of Alzheimer-type dementia (Kamer AR, et al. Alzheimer' s Dement. 2008, 4 242-250).

Separately from intracerebral inflammation, mild systemic inflammation is associated with a cognitive function decrease and a hippocampal capacity decrease (Marsland AL, et al: Biol Psychiatry, 64: 484-490, 2008).

Mild systemic inflammation increases risks of the Alzheimer's disease onset (Engelhart MJ, et al: Arch Neurol, 61: 668-672, 2004); (Tobinick EL: Neurology, 70: 1222-1223, 2008).

When the patients who contracted a disease for periodontal disease with Alzheimer-type dementia and the Alzheimer-type dementia patients who did not contract a disease for periodontal disease were compared, the cognitive function of the patients who had it for periodontal disease showed a significantly low (Kamer AR, et al. J Alzheimer’s Dis. 2012, 28: 613-624).

The contribution of the TREM2 mutation in the gene in Alzheimer's disease is reported, and the contribution of inflammation in the mechanism of pathogenesis attracts attention some other time (Jonsson T, et al: N Engl J Med, 368: 107-116, 2013).

Thus, it is reported that the cause of the Alzheimer-type dementia is inflammation.

In addition,
The trial as the basic treatment of Alzheimer-type dementia with made anti-amyloid β vaccine was discontinued because of meningoencephalitis by a hypothesis that a cause of Alzheimer-type dementia was amyloid β. However, in 2014 Lannfelt et al. reported that though amyloid β accumulation of the brain tissue of subjects was relieved, but was not able to inhibit progression of dementia of subjects in the subsequent course (Lannfelt L: et al: Amyloid-β-directed immunotherapy for Alzheimer' s disease. J Intern Med. 275: 284-295, 2014.).

It is easily understood that the cause of Alzheimer-type dementia is not amyloid β from these.
In other words, it is a matter of course, as the developers of anti-amyloid β vaccine understand the etiology of Alzheimer-type dementia and mild cognitive impairment by mistake, they cannot prevent Alzheimer-type dementia depending on anti-amyloid β vaccine.

The amyloid β deposition in the brain tissue can conclude that it is results by amyloid β depressed metabolism for functional decline of brain cells not a cause of Alzheimer-type dementia.
Also, the cause is not the tau protein.
The international Alzheimer's disease researcher of 37 Michael T Heneka et al. emphasized that an encephalitis symptom in Alzheimer's disease was critical cause in 2015 (Heneka MT, et al, Lancet Neurol. 14, 388-405, 2015). Nevertheless, I think that we have wasted long time and vast costs because we devoted ourselves to a β amyloid theory.

Furthermore, RO-8 can recover various kinds of disease including the disease that we were not regarding as immune disorders including Parkinson's disease and the glaucoma other than the disease mentioned above not a current symptomatic treatment fundamentally. (the video of the episode of care of Parkinson's disease is going to be released in a few months)
It is a clear fact that we cannot let these diseases heal with the immunosuppressive drug including NSAIDs and the steroid even if caused by activation of the immune system that the disease that mentioned above inflames.
Major depression disorder appears as a side effect with the steroid, but RO-8 lets more than 95% of the major depression heal immediately as had presented in WPA2015.

As a matter of course, it is thought that RO-8 can extend healthy life expectancy drastically if RO-8 stops inflammatory cytokine activity with the physical chronic inflammation.

Eradicative medicine of Alzheimer-type dementia, MCI, OAB (over active bladder) and the chronic kidney disease (CKD) does not exist besides RO-8.
It is thought that the time for dozens of years is necessary even if able to understand that the cause of these diseases is inflammatory cytokine as had shown here because the immune system is very complicated to make an eradicative medicine except RO-8.
On the other hand, RO-8 is a crude drug and can use it as a therapeutic drug immediately.

Please read an article to publish later.

The person who wants to conduct a supplementary examination may go anytime.

Please inform me of these patent rights which wants to obtain the transfer or enforcement right.

E-mail: atopic@bridge.ocn.ne.jp